HARROW, INC.: management transactions · United States · SEC (Form 4)

About HARROW, INC.

Harrow, Inc. is a United States-based healthcare company listed on the Nasdaq market under the ticker HROW. The company is headquartered in Nashville, Tennessee, United States, and is best understood as a specialized ophthalmic pharmaceutical platform rather than a broad diversified drugmaker. For international investors, Harrow occupies a niche position in eye care, with a strategy focused on accessibility, product availability, and physician-oriented commercial execution. Harrow’s modern identity was shaped by a strategic pivot that began in 2019. At that time, the company narrowed its focus to ophthalmology, rebranded as Harrow, Inc., and relocated its corporate headquarters to Nashville. This repositioning was intended to support a more concentrated growth strategy built around eyecare pharmaceuticals. Since then, Harrow has expanded through a series of acquisitions and commercial partnerships, building a broader portfolio of branded ophthalmic products alongside its established compounded-pharmacy business. Operationally, the company is built around two main engines. The first is ImprimisRx, its ophthalmology-focused compounding business, which supplies customized formulations used by eyecare professionals. The second is a growing portfolio of branded and FDA-approved ophthalmic medicines. Key products highlighted by the company include IHEEZO, VEVYE, and TRIESENCE, as well as other offerings used in the treatment of dry eye disease, glaucoma, allergies, infections, and selected ophthalmic inflammatory or surgical indications. Harrow also emphasizes patient-access programs and distribution solutions designed to improve affordability and ease of use for prescribers and patients. From a competitive standpoint, Harrow’s strength lies in specialization. Rather than competing as a large-scale general pharmaceutical company, it targets a focused segment of the ophthalmology market where service quality, product access, and formulary positioning matter greatly. That niche approach gives Harrow a differentiated commercial profile, particularly in North America, where the company’s business is concentrated. Its competitive advantage comes from combining a branded portfolio, compounding capabilities, and physician relationships under one umbrella. Recent developments indicate continued execution of the company’s growth plan. In 2025, Harrow launched or expanded access initiatives such as HAFA, extended pharmacy-network support for VEVYE, and announced an agreement to acquire Melt Pharmaceuticals, a clinical-stage company focused on non-opioid, non-IV sedation therapies. Harrow also reaffirmed its 2025 revenue guidance of $270 million to $280 million and later reported its full-year 2025 results in March 2026, underscoring management’s focus on scaling the business. For investors tracking SEC Form 4 insider transactions, HROW remains a high-conviction specialty healthcare name whose performance depends on product adoption, commercial execution, regulatory compliance, and successful integration of acquisitions. In short, Harrow is a Nasdaq-listed United States ophthalmic specialist with a still-evolving growth story and a clear focus on the North American eye-care market.